*MEREO BIOPHARMA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE HIGHLIGHTS
*MEREO BIOPHARMA GROUP PLC - QTRLY LOSS PER SHARE $0.02
*MEREO BIOPHARMA GROUP PLC - QTRLY REVENUE $500,000
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 12-AUG-202511:35:56.227 GMT